The Use of Intralesional Sodium Thiosulfate to Dissolve Facial Nodules From Calcium Hydroxylapatite.

FAA1505, FAA1514, FAA1552; Meditoxin, Medytox, Inc., Seoul, Korea), letibotulinumtoxin A (Batch No. HUA15030, HUA15058, HUA115062; Botulax, Hugel, Inc., Seoul, Korea), and prabotulinumtoxin A (Batch No. 991451, 991452, 991453; Nabota, Daewoong Pharmaceutical Co. Ltd., Seoul, Korea). Two types of BTX-A used in this study have been approved by the FDA (onabotulinumtoxin A and prabotulinumtoxin A). Two vials of each BTX-A were used. Each vial, containing 100 U of BTX-A, was reconstituted with 2.5 mL of sterile saline solution and stored at room temperature (20 6 5 C) for 12 weeks. Toxin activity and quality assessment were conducted at 0, 2, 4, 8, and 12 weeks after dilution. Each BTX-A was abbreviated as follows: onabotulinumtoxin A: Toxin 1, neuronox: Toxin 2, letibotulinumtoxin A: Toxin 3, and prabotulinumtoxin A: Toxin 4. Animals